Cargando…

Editorial: Inflammation and Fibrosis in the Gastrointestinal Tract and Liver: Mechanisms and Targets

Detalles Bibliográficos
Autores principales:	Weiskirchen, Ralf, Sorrentino, Dario, Stremmel, Wolfgang R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497695/ https://www.ncbi.nlm.nih.gov/pubmed/34630128 http://dx.doi.org/10.3389/fphar.2021.773228

Ejemplares similares

Cellular Mechanisms of Liver Fibrosis
por: Acharya, Pragyan, et al.
Publicado: (2021)

Editorial: Insights in Gastrointestinal and Hepatic Pharmacology: 2021
por: Weiskirchen, Ralf, et al.
Publicado: (2022)

Editorial: Cancer of gastrointestinal tract: Novel insight into the molecular mechanisms related to inflammation and therapeutic targets
por: Banerjee, Aditi, et al.
Publicado: (2022)

Editorial: New compounds, novel targets and mechanism study in inflammation-associated liver diseases
por: Wu, Baoming
Publicado: (2022)

Commentary: Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury
por: Weiskirchen, Ralf
Publicado: (2019)

Unresolved basic issues in hepatology
por: Weiskirchen, Ralf, et al.
Publicado: (2021)

Therapeutic strategies in Wilson disease: pathophysiology and mode of action
por: Stremmel, Wolfgang, et al.
Publicado: (2021)

Editorial: Gastrointestinal and Liver Effects of Fruits and Their Synergism With Drug Therapy: Exploring Possible Mechanisms of Action
por: Wanderley, Almir Gonçalves, et al.
Publicado: (2022)

Editorial: Molecular Mechanisms and New Therapeutic Targets in Epithelial to Mesenchymal Transition (EMT) and Fibrosis
por: Battistelli, Cecilia, et al.
Publicado: (2020)

Editorial: Targeting the Chemoattractant System in Inflammation
por: Hosoya, Tadashi, et al.
Publicado: (2021)

Editorial: Novel Therapeutic Targets and Emerging Treatments for Fibrosis
por: Samuel, Chrishan S., et al.
Publicado: (2017)

Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis
por: Schon, Hans-Theo, et al.
Publicado: (2016)

The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis—a narrative review article
por: Stremmel, Wolfgang, et al.
Publicado: (2021)

Phosphatidylcholine Passes by Paracellular Transport to the Apical Side of the Polarized Biliary Tumor Cell Line Mz-ChA-1
por: Stremmel, Wolfgang, et al.
Publicado: (2019)

Editorial: Pharmacological Approaches Targeting Neutrophilic Inflammation
por: Chernyak, Boris V., et al.
Publicado: (2021)

Editorial: Targeting inflammation to prevent complications in stroke
por: Varela, Lourdes M., et al.
Publicado: (2023)

Editorial: Molecular mechanisms and new therapeutic targets in epithelial to mesenchymal transition (EMT) and fibrosis, volume II
por: Battistelli, Cecilia, et al.
Publicado: (2022)

Vitamin A: too good to be bad?
por: Chen, Guoxun, et al.
Publicado: (2023)

Editorial: Liver Myofibroblasts
por: Kanta, Jiri, et al.
Publicado: (2016)

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
por: Blas-García, Ana, et al.
Publicado: (2022)

Editorial: Innovative Biologics and Drugs to Target Renal Inflammation
por: Griffin, Matthew D., et al.
Publicado: (2020)

Editorial: Targeting Monocytes/Macrophages to Treat Atherosclerotic Inflammation
por: Corti, Alessandro, et al.
Publicado: (2020)

Editorial: Advances in the potential treatments of gastrointestinal and liver diseases: addressing the public health burden
por: Turcu-Stiolica, Adina, et al.
Publicado: (2023)

Advances in Imaging of Inflammation, Fibrosis, and Cancer in the Gastrointestinal Tract
por: Harold, Kylene M., et al.
Publicado: (2022)

Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step
por: Weiskirchen, Ralf
Publicado: (2016)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

The Roles and Mechanisms of lncRNAs in Liver Fibrosis
por: Wang, Zhifa, et al.
Publicado: (2021)

Editorial: Discovering novel anticancer molecules and revealing the pharmacological mechanism of gastrointestinal carcinoma
por: Xia, Yong, et al.
Publicado: (2022)

Editorial: Pathophysiological and clinical advances in asthmatic inflammation from the nasopharynx to the peripheral airway in the respiratory tract systems
por: Koga, Yasuhiko, et al.
Publicado: (2023)

Editorial: Resolution of inflammation: Mechanisms, mediators and biomarkers: Volume II
por: Patrignani, Paola, et al.
Publicado: (2022)

Editorial: Pharmacological approaches targeting neutrophilic inflammation: Volume II
por: Sokolov, Alexey V., et al.
Publicado: (2022)

Editorial: Inflammation and immune diseases: Molecular targets for pathogenesis and treatment
por: Wu, Fan-Rong
Publicado: (2023)

Editorial: The Cell Types of Fibrosis
por: Murray, Lynne A.
Publicado: (2016)

The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2
por: Stremmel, Wolfgang, et al.
Publicado: (2019)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Intrahepatic T(H)17/T(Reg) Cells in Homeostasis and Disease—It’s All About the Balance
por: Drescher, Hannah K., et al.
Publicado: (2020)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Editorial: Ferroptosis as a novel therapeutic target for inflammation-related diseases
por: Liang, Yongyi, et al.
Publicado: (2023)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022)

Editorial: Natural product treatment of gastrointestinal diseases
por: Sun, Mingyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3oq8vtm59bdgqn5kg3uljqh091